Ability to successfully conduct hostile takeovers of companies
Ability to forge BD contracts and creative payment strategies
Ability to successfully merge with other companies
Alliances or partnerships with other companies
Identify, negotiate, and often implement deals that align with corporate strategy
Create and negotiate deals that bring new and innovative ideas into the company
Assist the marketing arm of the company with promoting the company
Monitor acquisition and divestiture deals.
Marketing, Clinical Development, and Regulatory
Regulatory, Legal, and Marketing
Discovery, Development, and Regulatory
Clinical Development, Marketing, and Discovery
Immediately goes into processing
Goes to a secondary approval committee
Stays in BD to advance to the next step
It goes back to the other company until their BD team accepts it
Discounted cash flow
Scientific risk-aversion analysis
BD, Legal, Finance
Marketing, Legal, BD
Discovery, Development, BD
Marketing, Development, Finance
Description of the business relationship
Schedule of payments
A. Co-marketing B. Co-promotion C. Manufacturing or supply D. Marketing-Licensing
A. Co-Marketing B. Joint Venture C. Market-Licensing D. R&D and Marketing Licensing
A. Joint Venture B. Product Acquisition C. Market-Licensing D. Co-Promotion
A. Product acquisition B. Joint Venture C. Market-Licensing D. Manufacturing or Supply
In-licensing and Acquisitions
Cooperative Development and Commercialization
Out-Licensing and Divestiture
A deal with contingent terms.
A deal with a "test/no fault" clause.
When a deal is structured so that the success of the initial product triggers mutual obligations with respect to other products.
When a deal is structured so that one party has the option of backing out before the final negotiations, and the other party is aware of this fact.
It will be based on the value assigned to the asset and decisions about how that value is to be shared.
It will be based upon the total value of the companies entering into the negotiations.
It will be based on the value that each party brings to the deal.
The FDA must assign the value of the product in question.
A product that has FDA approval
A late stage product
An early stage product
A product that is undergoing off-label investigator trials
By working with the legal team to product airtight contracts that absolves them of any risk.
Through the careful structuring of deal payments.
By only entering into negotiations regarding late stage compounds.
By employing Steve Jaben to handle their legal affairs.
Reoccurring payments that happen in predefined intervals.
Payments that are based on sales performance.
Where one party leaves bags of money at certain milemarkers along the interstate.
Payments that are contingent on the achievement of certain development or commercialization goals.
When the joint venture would create antitrust concerns through less competition in the market.
The FDA must always approve BD deals between companies.
In cases where the contract calls for a change in manufacturing facilities.
None. Approval is received from internal regulatory bodies only.
Deal evaluation and closure
The C-Suite (CEO, COO, CFO)
Leader of Strategic Marketing
Both in-licensing and out-licensing
Neither in-licensing or out-licensing
Angel food cake with strawberries.
New running shoes with speedy red laces.
W. Lawrence Bragg (back when he was younger and won, of course, not the older gentleman)
Coffee, coffee, and more coffee.
All of the above.